Anthony Coles - Regeneron Pharmaceuticals Independent Director

REGN -- USA Stock  

Earning Report: November 5, 2019  

  Director
Dr. N. Anthony Coles, M.D., is Independent Director of the Company. has served as Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, since October 2014. Prior to this, from October 2013, Dr. Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer, and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biopharmaceutical company. Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck Co., Inc., BristolMyers Squibb Company, and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporationrationration of America Holdings, Campus Crest Communities, Inc., and CRISPR Therapeutics AG. Dr. Coles was a director of McKesson Corporationrationration since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors.
Age: 57  Director Since 2017      
914 847-7000  www.regeneron.com

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3 M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Jeffrey KindlerPerrigo Company Plc
2017
Geoffrey ParkerPerrigo Company Plc
2016
Herman MorrisPerrigo Company Plc
1999
Bharat DoshiDr Reddys Laboratories Ltd
2016
Jacqualyn FousePerrigo Company Plc
2012
Sanjay KhoslaZoetis
2013
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Gary CohenPerrigo Company Plc
2009
Gregory NordenZoetis
2013
Laurie BrlasPerrigo Company Plc
2016
Allan ObermanDr Reddys Laboratories Ltd
2019
David BullockOrigin Agritech Limited
2015
Robert ScullyZoetis
2013
Bruce CarterDr Reddys Laboratories Ltd
2008
Alan GarberVertex Pharmaceuticals Incorpor
2017
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Gary KunklePerrigo Company Plc
2009
Ellen HoffingPerrigo Company Plc
2008
Fei WangOrigin Agritech Limited
2019
Shikha SharmaDr Reddys Laboratories Ltd
2019

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

REI-UN   
Purchased over 100 shares of
few hours ago
Traded for 24.76
OTEX   
Purchased over 200 shares of
few hours ago
Traded for 53.38
KXS   
Purchased over 60 shares of
few hours ago
Traded for 78.1
IFC   
Purchased over 40 shares of
few hours ago
Traded for 97.23
GDI   
Purchased over 100 shares of
few hours ago
Traded for 29.6
Additionally take a look at Your Equity Center. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Search macroaxis.com